Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma	Active, not recruiting	Phase 2	2026-04-17		NCT03971409

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Array BioPharma	3
Breast Cancer Research Foundation	40
Gilead Sciences	180
Hoosier Cancer Research Network	7
Johns Hopkins University	579
Laura Huppert, MD, BA	2
Pfizer	431
Translational Breast Cancer Research Consortium	19

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Abramson Cancer Center, University of Pennsylvania	Philadelphia	United States	3
Baylor College of Medicine	Houston	United States	306
Dana-Farber Cancer Institute	Boston	United States	626
Duke Cancer Institute	Durham	United States	47
Georgetown University	Washington D.C.	United States	21
Mayo Clinic	Rochester	United States	664
O'Neal Comprehensive Cancer Center	Birmingham	United States	1
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University	Baltimore	United States	1
UNC Lineberger Comprehensive Cancer Center	Chapel Hill	United States	243
University of California, San Francisco	San Francisco	United States	294
University of Chicago Medicine Comprehensive Cancer Center	Evergreen Park	United States	1
Vanderbilt University Ingram Cancer Center	Nashville	United States	1